Satellos Bioscience Inc
9.12
CAD
-0.40
(-4.20%)
ISIN
CA80401L8033
CUSIP
80401L803
Return %
Stock
S&P 500
1Y
2.70
14.20
3Y
90.00
81.12
5Y
-51.28
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Frank Gleeson
- Full Time Employees
- 18
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Royal Bank Plaza Toronto ON Canada M5J 2J1
- IPO Date
- Jan 7, 2008
- Website
- satellos.com
- Similar Companies
- Business
- Satellos Bioscience Inc. is a Canada-based clinical-stage biotechnology company specializing in the development of small molecule therapeutics to treat degenerative muscle diseases, primarily Duchenne muscular dystrophy (DMD). The company employs a proprietary discovery platform, MyoReGenX, which focuses on muscle stem cell polarity to identify and develop treatments that restore the body’s natural muscle repair and regeneration processes. Satellos' lead product candidate is SAT-3247, an oral small molecule drug designed as a potential disease-modifying therapy for DMD, targeting muscle repair deficits. Satellos operates in the biotechnology and pharmaceutical industry, conducting research and clinical development mainly in Canada, the United States, and Australia, with subsidiaries in these regions. Its therapeutic pipeline centers on correcting muscle stem cell polarity to enhance muscle regeneration, addressing a critical unmet need in degenerative muscle diseases. Recent major developments include the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and parallel regulatory filings globally to initiate a Phase 2 clinical trial of SAT-3247 in children with Duchenne muscular dystrophy, with patient enrollment expected by the end of 2025. The company has reported promising Phase 1a/b clinical trial results demonstrating safety, tolerability, and early functional improvements such as doubled grip strength and improved lung function in adult patients. Satellos has also initiated a long-term follow-up study (LT-001) in adult males and is expanding clinical development with planned global trials. Key recent operational changes include new leadership appointments, notably the naming of Dr. Wildon Farwell as Chief Medical Officer, who is spearheading the advancement of SAT-3247 into global Phase 2 trials, and ongoing participation in scientific conferences to present trial data. The company also raised C$1.04 million through warrant exercises in Q3 2025 to support its clinical programs and strategic growth. Satellos Bioscience Inc. was founded in 2014 and is headquartered in Ottawa, Ontario, Canada. It positions itself as a pioneer in regenerative medicine focusing on life-improving treatments for degenerative muscle conditions, leveraging novel small molecule approaches to reset the body's innate muscle repair mechanisms. This description covers Satellos' core products and services, geographic focus, industry presence, and the latest strategic and clinical developments up to late 2025.
Company News
Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated “Moderate Buy” by Wall Street Brokerages
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
Satellos to Participate in Upcoming Investor Conferences
Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More